中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (11): 852-857.doi: 10.19401/j.cnki.1007-3639.2018.11.009

• 综述 • 上一篇    下一篇

免疫检查点抑制剂疗效相关的生物标志物研究进展

赵海云,吉 芃,李小光,胡 欣   

  1. 复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2018-11-30 发布日期:2018-12-14
  • 通信作者: 胡 欣 E-mail:xinhu@fudan.edu.cn
  • 基金资助:
    国家自然科学基金资助项目(81672601);上海市科委国际合作项目(15410724000);科技部“精准医学”国家重点研发计划(MOST2016YFC0900302)。

Research progress of biomarkers associated with efficacy of immune checkpoint blockade

ZHAO Haiyun, JI Peng, LI Xiaoguang, HU Xin   

  1. Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2018-11-30 Online:2018-12-14
  • Contact: HU Xin E-mail: xinhu@fudan.edu.cn

摘要: 肿瘤免疫治疗因其显著的生存获益已成为除手术、化疗、放疗及靶向治疗之外有效的新型肿瘤治疗手段。免疫检查点抑制剂作为肿瘤免疫治疗的方法之一,目前已被批准用于多种晚期肿瘤的治疗。尽管部分肿瘤患者能从中获益,但该抑制剂临床使用过程中的免疫相关不良反应、原发性耐药和继发性耐药等问题限制了其在临床上的广泛应用。免疫检查点抑制剂疗效相关的生物标志物研究有助于患者筛查及个体化治疗,对规范免疫抑制剂单药治疗或联合治疗具有重要意义。

关键词: 免疫检查点抑制剂, PD-L1, 肿瘤突变负荷, 肠道微生物菌群, 血液学标志物

Abstract: Cancer immunotherapy has been a novel and efficient cancer therapeutic strategy besides surgery, chemotherapy, radiotherapy and targeted therapy for its durable clinical benefit. Immune checkpoint blockade, as one of the cancer immunotherapy strategies, has been approved for the treatment of many advanced cancers. However, the immune adverse effects and drug resistance are the main challenges limiting its clinical applications. It will be of great significance to explore biomarkers associated with efficacy of immune checkpoint blockade.

Key words: Immune checkpoint blockade, PD-L1, Tumor mutational burden, Commensal bacteria, Haematological biomarker